CSIMarket
 


Halozyme Therapeutics Inc   (HALO)
Other Ticker:  
 
 

HALO's Capital Expenditures Growth by Quarter and Year

Halozyme Therapeutics Inc 's Capital Expenditures results by quarter and year




HALO Capital Expenditures (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December 2.60 2.34 0.16 0.18
III Quarter September 2.94 1.01 0.50 0.52
II Quarter June 0.00 0.97 0.00 0.11
I Quarter March 11.38 0.49 1.70 0.64
FY   16.92 4.81 2.36 1.45



HALO Capital Expenditures fourth quarter 2023 Y/Y Growth Comment
Halozyme Therapeutics Inc reported Capital Expenditures increase of 10.94% year on year in the fourth quarter 2023, to $ 2.60 millions, this is lower than Halozyme Therapeutics Inc 's recent average Capital Expenditures rise of 69.59%.

According to the results reported in the fourth quarter 2023, Halozyme Therapeutics Inc achieved the best Capital Expenditures growth in Biotechnology & Pharmaceuticals industry. While Halozyme Therapeutics Inc ' s Capital Expenditures growth of 10.94% ranks overall at the positon no. 48 in the fourth quarter 2023.




HALO Capital Expenditures ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December 10.94 % 1362.5 % -11.11 % -83.64 %
III Quarter September 191.09 % 102 % -3.85 % -62.04 %
II Quarter June - - - -88.17 %
I Quarter March 2222.45 % -71.18 % 165.63 % -79.15 %
FY   251.68 % 103.81 % 62.76 % -77.59 %

Financial Statements
Halozyme Therapeutics Inc 's fourth quarter 2023 Capital Expenditures $ 2.60 millions HALO's Income Statement
Halozyme Therapeutics Inc 's fourth quarter 2022 Capital Expenditures $ 2.34 millions Quarterly HALO's Income Statement
New: More HALO's historic Capital Expenditures Growth >>


HALO Capital Expenditures (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December -11.7 % 131.68 % -68 % -65.38 %
III Quarter September - 4.12 % - 372.73 %
II Quarter June - 97.96 % - -82.81 %
I Quarter March 386.32 % 206.25 % 844.44 % -41.82 %
FY (Year on Year)   251.68 % 103.81 % 62.76 % -77.59 %




Capital Expenditures fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #0
Healthcare Sector #7
Overall #48

Capital Expenditures Y/Y Growth Statistics
High Average Low
637.73 % 69.59 % -122.24 %
(Dec 31 2022)   (Mar 31 2022)
Capital Expenditures fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #0
Healthcare Sector #7
Overall #48
Capital Expenditures Y/Y Growth Statistics
High Average Low
637.73 % 69.59 % -122.24 %
(Dec 31 2022)   (Mar 31 2022)

Capital Expenditures by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Halozyme Therapeutics Inc 's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
865.34 % 80.66 % -100 %
(Dec 31 2020)  


HALO's IV. Quarter Q/Q Capital Expenditures Comment
In the IV. Quarter 2023 Halozyme Therapeutics Inc reported drop in Capital Expenditures from the previous quarter by -11.7% to $ 2.60 millions, from $ 2.94 millions released in the previous reporting period.

Although cyclical circumstance commonly energize IV. Quarter 2023 results, this plainly has not been sufficient to salvage HALO's IV. Quarter performance, Kobe Maes, Healthcare sector contributor located in Antwerpen pointed out.

Within Biotechnology & Pharmaceuticals industry 6 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Halozyme Therapeutics Inc 's Capital Expenditures growth quarter on quarter, overall rank is 505.


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #7
Healthcare Sector #58
Overall #505
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #7
Healthcare Sector #58
Overall #505
Capital Expenditures Q/Q Growth Statistics
High Average Low
865.34 % 80.66 % -100 %
(Dec 31 2020)  


HALO's IV. Quarter Q/Q Capital Expenditures Comment
In the IV. Quarter 2023 Halozyme Therapeutics Inc reported drop in Capital Expenditures from the previous quarter by -11.7% to $ 2.60 millions, from $ 2.94 millions released in the previous quarter.

Even periodic circumstance were not able to recover the IV. Quarter for the Halozyme Therapeutics Inc , Kobe Maes, Healthcare sector contributor located in Antwerpen pointed out, he detected further headwinds onward for HALO and wrote that average sequential Capital Expenditures growth is at 80.66% for HALO.

Within Biotechnology & Pharmaceuticals industry 6 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Halozyme Therapeutics Inc 's Capital Expenditures growth quarter on quarter, overall rank is 505.


Halozyme Therapeutics Inc 's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
Cumulative Capital Expenditures 12 Months Ending $ 0.00 $ 0.00 $ 0.00 $ 15.70 $ 4.81
Y / Y Capital Expenditures Growth (TTM) - - - - 637.73 %
Year on Year Capital Expenditures Growth Overall Ranking # 3 # 16 # 59 # 113 # 1769
Seqeuential Capital Expenditures Change (TTM) - - - 226.34 % 83.31 %
Seq. Capital Expenditures Growth (TTM) Overall Ranking # 48 # 395 # 581 # 949 # 1295




Cumulative Capital Expenditures growth Comment
Halozyme Therapeutics Inc realized trailing twelve months Capital Expenditures of $ 0 millions, in the Dec 31 2023, compare to Capital Expenditures of $ 5 millions a year ago.

Halozyme Therapeutics Inc achieved highest trailing twelve month year on year Capital Expenditures growth. While Total ranking has impoved so far to 3, from total ranking in previous quarter at 16.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
637.73 %
69.59 %
-122.24 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 0
Healthcare Sector # 0
Overall # 3

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
637.73 %
69.59 %
-122.24 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 0
Sector # 7
S&P 500 # 48
Cumulative Capital Expenditures growth Comment
Halozyme Therapeutics Inc realized trailing twelve months Capital Expenditures of $ 0 millions, in the Dec 31 2023, compare to Capital Expenditures of $ 5 millions a year ago.

Halozyme Therapeutics Inc achieved highest trailing twelve month year on year Capital Expenditures growth. While Total ranking has impoved so far to 3, from total ranking in previous quarter at 16.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
637.73 %
69.59 %
-122.24 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 0
Healthcare Sector # 0
Overall # 3

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
637.73 %
69.59 %
-122.24 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 0
Sector # 7
S&P 500 # 48




Other Capital Expenditures Growth
Biotechnology & Pharmaceuticals Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
HALO's Capital Expenditures Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for HALO's Competitors
Capital Expenditures Growth for Halozyme Therapeutics Inc 's Suppliers
Capital Expenditures Growth for HALO's Customers

You may also want to know
HALO's Annual Growth Rates HALO's Profitability Ratios HALO's Asset Turnover Ratio HALO's Dividend Growth
HALO's Roe HALO's Valuation Ratios HALO's Financial Strength Ratios HALO's Dividend Payout Ratio
HALO's Roa HALO's Inventory Turnover Ratio HALO's Growth Rates HALO's Dividend Comparisons



Companies with similar Capital Expenditures drop for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Dec 31 2023
Gilead Sciences Inc 18.78%$ 18.785 millions
Butterfly Network inc 18.38%$ 18.379 millions
Protalix Biotherapeutics inc 17.37%$ 17.371 millions
Integer Holdings Corporation17.15%$ 17.145 millions
Abcellera Biologics Inc 17.04%$ 17.040 millions
Iovance Biotherapeutics Inc 16.78%$ 16.777 millions
Zoetis Inc 15.79%$ 15.789 millions
West Pharmaceutical Services Inc 14.54%$ 14.542 millions
Edwards Lifesciences Corporation14.03%$ 14.029 millions
Pulmonx Corporation13.64%$ 13.636 millions
Phibro Animal Health Corporation11.61%$ 11.610 millions
Halozyme Therapeutics Inc 10.75%$ 10.751 millions
Prestige Consumer Healthcare Inc 10.70%$ 10.704 millions
Encompass Health Corporation10.36%$ 10.362 millions
Select Medical Holdings Corp9.68%$ 9.683 millions
Owens and Minor inc9.51%$ 9.509 millions
Qiagen N v 9.02%$ 9.017 millions
Option Care Health Inc 8.98%$ 8.977 millions
Medpace Holdings Inc 8.04%$ 8.039 millions
Jazz Pharmaceuticals Plc7.72%$ 7.720 millions
Viatris Inc 7.68%$ 7.677 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com